25135587|t|Ivabradine Versus Beta-Blockers in Patients with Conduction Abnormalities or Left Ventricular Dysfunction Undergoing Cardiac Surgery.
25135587|a|INTRODUCTION: In patients with conduction abnormalities or left ventricle (LV) dysfunction the use of beta-blockers for post cardiac surgery rhythm control is difficult and controversial, with a paucity of information about other drugs such ivabradine used postoperatively. The objective of this study was to compare the efficacy and safety of ivabradine versus metoprolol used perioperatively in cardiac surgery patients with conduction abnormalities or LV systolic dysfunction. METHODS: This was an open-label, randomized clinical trial enrolling 527 patients with conduction abnormalities or LV systolic dysfunction undergoing coronary artery bypass grafting or valvular replacement, randomized to take ivabradine or metoprolol, or metoprolol plus ivabradine. The primary endpoints were the composites of 30-day mortality, in-hospital atrial fibrillation (AF), in-hospital three-degree atrioventricular block and need for pacing, in-hospital worsening heart failure (HF; safety endpoints), duration of hospital stay and immobilization and the above endpoint plus in-hospital bradycardia, gastrointestinal symptoms, sleep disturbances, cold extremities (efficacy plus safety endpoint). RESULTS: Heart rate reduction and prevention of postoperative AF or tachyarrhythmia with combined therapy was more effective than with metoprolol or ivabradine alone during the immediate postoperative management of cardiac surgery patients. In the Ivabradine group, the frequency of early postoperative pacing and HF worsening was smaller than in the Metoprolol group and in combined therapy group. The frequency of primary combined endpoint was lower in the combined Ivabradine + Metoprolol group compared with the monotherapy groups. CONCLUSION: Considering efficacy and safety, the cardiac rhythm reduction after open heart surgery in patients with conduction abnormalities or LV dysfunction with ivabradine plus metoprolol emerged as the best treatment in this trial.
25135587	0	10	Ivabradine	Chemical	MESH:D000077550
25135587	35	43	Patients	Species	9606
25135587	49	73	Conduction Abnormalities	Disease	MESH:D054537
25135587	77	105	Left Ventricular Dysfunction	Disease	MESH:D018487
25135587	151	159	patients	Species	9606
25135587	165	189	conduction abnormalities	Disease	MESH:D054537
25135587	193	224	left ventricle (LV) dysfunction	Disease	MESH:D020257
25135587	375	385	ivabradine	Chemical	MESH:D000077550
25135587	478	488	ivabradine	Chemical	MESH:D000077550
25135587	496	506	metoprolol	Chemical	MESH:D008790
25135587	547	555	patients	Species	9606
25135587	561	585	conduction abnormalities	Disease	MESH:D054537
25135587	589	612	LV systolic dysfunction	Disease	MESH:D020257
25135587	687	695	patients	Species	9606
25135587	701	725	conduction abnormalities	Disease	MESH:D054537
25135587	729	752	LV systolic dysfunction	Disease	MESH:D020257
25135587	840	850	ivabradine	Chemical	MESH:D000077550
25135587	854	864	metoprolol	Chemical	MESH:D008790
25135587	869	879	metoprolol	Chemical	MESH:D008790
25135587	885	895	ivabradine	Chemical	MESH:D000077550
25135587	972	991	atrial fibrillation	Disease	MESH:D001281
25135587	993	995	AF	Disease	MESH:D001281
25135587	1023	1045	atrioventricular block	Disease	MESH:D054537
25135587	1089	1102	heart failure	Disease	MESH:D006333
25135587	1104	1106	HF	Disease	MESH:D006333
25135587	1212	1223	bradycardia	Disease	MESH:D001919
25135587	1225	1250	gastrointestinal symptoms	Disease	MESH:D012817
25135587	1252	1270	sleep disturbances	Disease	MESH:D012893
25135587	1384	1386	AF	Disease	MESH:D001281
25135587	1390	1405	tachyarrhythmia	Disease	MESH:D013610
25135587	1457	1467	metoprolol	Chemical	MESH:D008790
25135587	1471	1481	ivabradine	Chemical	MESH:D000077550
25135587	1553	1561	patients	Species	9606
25135587	1570	1580	Ivabradine	Chemical	MESH:D000077550
25135587	1636	1638	HF	Disease	MESH:D006333
25135587	1673	1683	Metoprolol	Chemical	MESH:D008790
25135587	1790	1800	Ivabradine	Chemical	MESH:D000077550
25135587	1803	1813	Metoprolol	Chemical	MESH:D008790
25135587	1960	1968	patients	Species	9606
25135587	1974	1998	conduction abnormalities	Disease	MESH:D054537
25135587	2002	2016	LV dysfunction	Disease	MESH:D020257
25135587	2022	2032	ivabradine	Chemical	MESH:D000077550
25135587	2038	2048	metoprolol	Chemical	MESH:D008790
25135587	Negative_Correlation	MESH:D008790	MESH:D013610
25135587	Negative_Correlation	MESH:D008790	MESH:D054537
25135587	Negative_Correlation	MESH:D000077550	MESH:D054537
25135587	Cotreatment	MESH:D000077550	MESH:D008790
25135587	Negative_Correlation	MESH:D000077550	MESH:D013610
25135587	Negative_Correlation	MESH:D008790	MESH:D001281
25135587	Positive_Correlation	MESH:D008790	MESH:D006333
25135587	Association	MESH:D000077550	MESH:D006333
25135587	Negative_Correlation	MESH:D008790	MESH:D020257
25135587	Negative_Correlation	MESH:D000077550	MESH:D020257
25135587	Negative_Correlation	MESH:D000077550	MESH:D018487
25135587	Negative_Correlation	MESH:D000077550	MESH:D001281

